BioSpace News Archive

Most drug addicts find it difficult to wean themselves away from the fatal substance and require a protracted therapy for that.

Biomerica Inc. announced that it has filed a new three year shelf registration statement on Form S-3 with the United States Securities and Exchange Commission to replace its previous three year shelf registration statement, which was declared effective by the SEC in July 2017.

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, announced it will release financial results for the second quarter ended June 30, 2020, after market close on Wednesday, August 5, 2020.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License Application (BLA) submission for Avance Nerve Graft has reached its enrollment target of 220 subjects

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the strengthening of its executive team with the appointment of Andrea Pirzkall, M.D. as Replimune’s Chief Medical Officer effective August 31 st , 2020. “We are very excited to have Andrea join the Replimune team as we aggressively advance our pipeline,” said Philip Astley-Sparke, Chief

Funding to accelerate development and commercial launch of Proteograph™ suite of reagents, instrument and software products to deliver on untapped promise of proteomics

LHC Group, Inc . (NASDAQ: LHCG) today announced details for the release of its results for the second quarter ended June 30, 2020. LHC Group plans to issue its earnings release after the market closes on Wednesday, August 5, 2020, and will host a conference call on Thursday, August 6, 2020, at 10:00 a.m. Eastern time. The toll-free number to call for this interactive teleconference is (866) 393-1608 (international callers: (973) 890-8327).

Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors

Phase 2/3 study process initiated in Brazil and Mexico The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites Potential submission of emergency use applications planned for Q4/2020 Enrollment in parallel U.S. Phase 2 study in severe COVID-19 patients expected to be completed in August TEL-AVIV, Israel and

Hackensack Meridian Health (HMH) in Edison, New Jersey, and Genomic Testing Cooperative (GTC), Irvine, California, announced today an agreement to establish a next generation sequencing reference laboratory for molecular profiling. T